FDA Inspection 988237 — Takeda Pharmaceuticals USA, Inc.

Takeda Pharmaceuticals USA, Inc. — FEI 3002393210

The FDA completed an inspection of Takeda Pharmaceuticals USA, Inc. on September 9, 2016 in Deerfield, IL. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 3 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
September 9, 2016
Fiscal Year
2016
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Deerfield, IL (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)

Citations

IDCFRDescription
672821 CFR 314.80(b)Failure to review ADE information
673221 CFR 314.80(c)(1)(i)Late submission of 15-day report
673621 CFR 314.80(c)(1)(ii)Submission of report follow-up